Poxel Secures Patent in China for Innovative Diabetes Treatment
Poxel SA, a clinical-stage biopharmaceutical company, has recently announced a significant milestone in its mission to develop cutting-edge treatments for chronic diseases. The company has successfully obtained a patent from China’s National Intellectual Property Administration (CNIPA) protecting its first-in-class drug, Imeglimin, specifically aimed at patients suffering from type-2 diabetes who also have moderate to severe renal impairment.
Importance of the Patent for Imeglimin
This newly granted patent ZL201980015603.X safeguards the use of Imeglimin until 2039, highlighting its revolutionary approach in addressing mitochondrial dysfunction—a condition commonly associated with type-2 diabetes. Given the alarming statistics regarding chronic kidney disease within the diabetic population in China, this patent paves the way for Poxel’s commitment to expanding Imeglimin's availability in this key market.
Chronic Kidney Disease and Diabetes
The connection between diabetes and kidney health cannot be overstated. In China, around 27% of diabetic patients—almost 32 million individuals—are also facing chronic kidney issues. Diabetes is recognized as a leading cause of kidney failure, necessitating dialysis or transplants, further emphasizing the urgency of developing safe and effective treatments like Imeglimin.
Poxel's Strategy for Development in China
As part of its strategic initiatives, Poxel is prioritizing China for the development and commercialization of Imeglimin. The company is currently in discussions to explore potential partnerships that could facilitate the successful introduction of this vital treatment to patients who desperately need it. With favorable regulations from the Japanese Agency for Pharmaceuticals and Medical Devices, the company aims to streamline development timelines, allowing for quicker patient access to this innovative therapy.
The Vision of Poxel’s CEO
Thomas Kuhn, the CEO of Poxel, expressed the company's commitment, stating that securing this patent aligns with the broader corporate strategy to fulfill the staggering medical needs of type-2 diabetic patients with renal complications in China. The plan isn’t just limited to China; Poxel is also focusing on expanding its reach into Southeast Asian countries and other territories to maximize the approval processes already achieved in Japan.
About Poxel SA
Poxel SA stands out as a leader in the field of biopharmaceuticals, dedicated to developing innovative treatments for various chronic conditions. The company has several promising projects in its pipeline, including PXL065, a treatment for metabolic dysfunction-associated steatohepatitis (MASH), which has shown promising results in its Phase 2 trials. Additionally, PXL770 is being developed for rare conditions such as adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD).
Poxel’s first-in-class product, TWYMEEG (Imeglimin), is already being marketed in Japan through a partnership with Sumitomo Pharma, leading to anticipated royalties and sales-based revenue for the company. Headquartered in Lyon, France, Poxel also has operational bases in Boston and Tokyo, strengthening its global presence.
Frequently Asked Questions
What is the significance of the new patent for Imeglimin?
The patent protects Imeglimin's use for type-2 diabetic patients with renal impairment, allowing Poxel to pursue marketing and development in China until 2039.
How many patients in China suffer from diabetes and chronic kidney disease?
Approximately 32 million diabetic patients in China are affected by chronic kidney disease, highlighting a critical need for effective treatments.
What is Imeglimin and how does it work?
Imeglimin is a first-in-class drug that targets mitochondrial dysfunction, which is often a crucial factor in managing type-2 diabetes, aiming to improve metabolic health.
Why is Poxel focusing on China for its treatment development?
China represents a major opportunity due to its large diabetic population with renal issues, and regulatory support from Japan may expedite the process.
What other products is Poxel developing?
Poxel is also working on PXL065 for MASH and PXL770 for rare diseases, demonstrating the company's commitment to addressing various health challenges.
